Cancer Biopsy Market by Product (Instruments, Kits & Consumables, Services), Type (Liquid Biopsies, Tissue Biopsies), Indication - Global Forecast 2023-2030

Cancer Biopsy Market by Product (Instruments, Kits & Consumables, Services), Type (Liquid Biopsies, Tissue Biopsies), Indication - Global Forecast 2023-2030


The Cancer Biopsy Market is projected to reach USD 67.14 billion by 2030 from USD 26.61 billion in 2022, at a CAGR of 12.26% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Cancer Biopsy Market.
  • Based on Product, market is studied across Instruments, Kits & Consumables, and Services. The Services is projected to witness significant market share during forecast period.
  • Based on Type, market is studied across Liquid Biopsies and Tissue Biopsies. The Tissue Biopsies is further studied across Needle Biopsies and Surgical Biopsies. The Needle Biopsies is further studied across Core Needle Biopsy and Fine Needle Aspiration. The Tissue Biopsies is projected to witness significant market share during forecast period.
  • Based on Indication, market is studied across Blood Cancers, Breast Cancer, Cervical Cancers, Colorectal Cancer, Kidney Cancers, Liver Cancers, Lung Cancers, Ovarian Cancers, Pancreatic Cancers, Prostate Cancers, and Skin Cancers. The Pancreatic Cancers is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Cancer Biopsy Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Cancer Biopsy Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Cancer Biopsy Market, highlighting leading vendors and their innovative profiles. These include Agena Bioscience, Inc., Agilent Technologies Inc., ANGLE PLC, Becton, Dickinson and Company, BIOCEPT, Inc., Danaher Corporation, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Freenome Holdings, Inc., GRAIL, Inc., Guardant Health, HelioHealth, Hologic, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, Lucence Health Inc., MDx Health, Myriad Genetics, Inc., Natera, Inc., OncoCyte Corp, Personalis Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., and Trovagene, Inc.

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Cancer Biopsy Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Cancer Biopsy Market?
  3. What is the competitive strategic window for identifying opportunities in the Cancer Biopsy Market?
  4. What are the latest technology trends and regulatory frameworks in the Cancer Biopsy Market?
  5. What is the market share of the leading vendors in the Cancer Biopsy Market?
  6. Which modes and strategic moves are suitable for entering the Cancer Biopsy Market?


Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Biopsy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing preference for non-invasive procedures
5.1.1.2. Emerging significance of cancer biopsies and tissue sectioning
5.1.1.3. Growing adoption of liquid cancer biopsies
5.1.2. Restraints
5.1.2.1. Low sensitivity and specificity of cancer biopsies
5.1.3. Opportunities
5.1.3.1. Technological advancements in cancer biopsy devices
5.1.3.2. Increasing R&D activities for novel cancer treatments
5.1.4. Challenges
5.1.4.1. Stringent regulatory requirements and unclear reimbursement scenarios
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Cancer Biopsy Market, by Product
6.1. Introduction
6.2. Instruments
6.3. Kits & Consumables
6.4. Services
7. Cancer Biopsy Market, by Type
7.1. Introduction
7.2. Liquid Biopsies
7.3. Tissue Biopsies
7.4.1. Needle Biopsies
7.4.2.1. Core Needle Biopsy
7.4.2.2. Fine Needle Aspiration
7.4.2. Surgical Biopsies
8. Cancer Biopsy Market, by Indication
8.1. Introduction
8.2. Blood Cancers
8.3. Breast Cancer
8.4. Cervical Cancers
8.5. Colorectal Cancer
8.6. Kidney Cancers
8.7. Liver Cancers
8.8. Lung Cancers
8.9. Ovarian Cancers
8.10. Pancreatic Cancers
8.11. Prostate Cancers
8.12. Skin Cancers
9. Americas Cancer Biopsy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Cancer Biopsy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Cancer Biopsy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Agena Bioscience, Inc.
13.1.2. Agilent Technologies Inc.
13.1.3. ANGLE PLC
13.1.4. Becton, Dickinson and Company
13.1.5. BIOCEPT, Inc.
13.1.6. Danaher Corporation
13.1.7. Epigenomics AG
13.1.8. Exact Sciences Corporation
13.1.9. F. Hoffmann-La Roche Ltd.
13.1.10. Freenome Holdings, Inc.
13.1.11. GRAIL, Inc.
13.1.12. Guardant Health
13.1.13. HelioHealth
13.1.14. Hologic, Inc.
13.1.15. Illumina, Inc.
13.1.16. Laboratory Corporation of America Holdings
13.1.17. Lucence Health Inc.
13.1.18. MDx Health
13.1.19. Myriad Genetics, Inc.
13.1.20. Natera, Inc.
13.1.21. OncoCyte Corp
13.1.22. Personalis Inc.
13.1.23. QIAGEN N.V.
13.1.24. Thermo Fisher Scientific, Inc.
13.1.25. Trovagene, Inc
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings